p90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in α-tropomyosin Glu180Gly transgenic mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 7, 2013, Pages

  Passariello, Catherine L ^a   Gayanilo, Marjorie ^a   Kritzer, Michael D ^a   Thakur, Hrishikesh ^a   Cozacov, Zoharit ^a   Rusconi, Francesca ^a   Wieczorek, David ^b   Sanders, Michael ^a   Li, Jinliang ^a   Kapiloff, Michael S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

tropomyosin; Fibrosis; Ribosomal S6 kinase

Indexed keywords

ALPHA TROPOMYOSIN; GLUTAMIC ACID; GLYCINE; P90 RIBOSOMAL S6 KINASE 3; S6 KINASE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARDIOMYOPATHY; CELL GROWTH; CONTROLLED STUDY; DIASTOLE; ENZYME INHIBITION; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENE MUTATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HISTOCHEMISTRY; LUNG EDEMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SYSTOLE; TRANSGENIC MOUSE;

Α-TROPOMYOSIN; FIBROSIS; RIBOSOMAL S6 KINASE;

ANIMALS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; GENOTYPE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHENOTYPE; PULMONARY EDEMA; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; STROKE VOLUME; TROPOMYOSIN; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84884970540     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00237.2013     Document Type: Article

References (29)

1. Amirak E, Fuller SJ, Sugden PH, Clerk A. p90 Ribosomal S6 kinases play a significant role in early gene regulation in the cardiomyocyte response to Gq-protein-coupled receptor stimuli, endothelin-1 and alpha1-adrenergic receptor agonists. Biochem J 450: 351-353, 2013.
2. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747-758, 2008.
3. Balza RO Jr, Misra RP. Role of the serum response factor in regulating contractile apparatus gene expression and sarcomeric integrity in cardiomyocytes. J Biol Chem 281: 6498-6510, 2006.
4. Bing W, Knott A, Redwood C, Esposito G, Purcell I, Watkins H, Marston S. Effect of hypertrophic cardiomyopathy mutations in human cardiac muscle alpha-tropomyosin (Asp175Asn and Glu180Gly) on the regulatory properties of human cardiac troponin determined by in vitro motility assay. J Mol Cell Cardiol 32: 1489-1498, 2000.
5. Edgley AJ, Krum H, Kelly DJ. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-beta. Cardiovasc Ther 30: e30-e40, 2012.
6. Gaffin RD, Pena JR, Alves MS, Dias FA, Chowdhury SA, Heinrich LS, Goldspink PH, Kranias EG, Wieczorek DF, Wolska BM. Longterm rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein. J Mol Cell Cardiol 51: 812-820, 2011.
7. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, and American College of Cardiology Foundation/American Heart Association Task Force on Practice G. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58: e212-e260, 2011.
8. Hanlon M, Sturgill TW, Sealy L. ERK2-and p90(Rsk2)-dependent pathways regulate the CCAAT/enhancer-binding protein-beta interaction with serum response factor. J Biol Chem 276: 38449-38456, 2001.
9. Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, Gonzalez A, Colan SD, Seidman JG, Diez J, Seidman CE. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363: 552-563, 2010.
10. Janknecht R, Hipskind RA, Houthaeve T, Nordheim A, Stunnenberg HG. Identification of multiple SRF N-terminal phosphorylation sites affecting DNA binding properties. EMBO J 11: 1045-1054, 1992.
11. Kimura TE, Jin J, Zi M, Prehar S, Liu W, Oceandy D, Abe JI, Neyses L, Weston AH, Cartwright EJ, Wang X. Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res 106: 961-970, 2010.
12. Kritzer MD, Li J, Dodge-Kafka K, Kapiloff MS. AKAPs: the architectural underpinnings of local cAMP signaling. J Mol Cell Cardiol 52: 351-358, 2012.
13. Le NT, Takei Y, Shishido T, Woo CH, Chang E, Heo KS, Lee H, Lu Y, Morrell C, Oikawa M, McClain C, Wang X, Tournier C, Molina CA, Taunton J, Yan C, Fujiwara K, Patterson C, Yang J, Abe J. p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction. Circ Res 110: 536-550, 2012.
14. Li J, Kritzer MD, Michel JJ, Le A, Thakur H, Gayanilo M, Passariello CL, Negro A, Danial JB, Oskouei B, Sanders M, Hare JM, Hanauer A, Dodge-Kafka K, Kapiloff MS. Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy. Circ Res 112: 128-139, 2013.
15. Li T, Liu Z, Hu X, Ma K, Zhou C. Involvement of ERK-RSK cascade in phenylephrine-induced phosphorylation of GATA4. Biochim Biophys Acta 1823: 582-592, 2012.
16. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 381: 242-255, 2013.
17. Michele DE, Gomez CA, Hong KE, Westfall MV, Metzger JM. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade. Circ Res 91: 255-262, 2002.
18. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104: 317-324, 2001.
19. Pena JR, Szkudlarek AC, Warren CM, Heinrich LS, Gaffin RD, Jagatheesan G, del Monte F, Hajjar RJ, Goldspink PH, Solaro RJ, Wieczorek DF, Wolska BM. Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 49: 993-1002, 2010.
20. Prabhakar R, Boivin GP, Grupp IL, Hoit B, Arteaga G, Solaro JR, Wieczorek DF. A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. J Mol Cell Cardiol 33: 1815-1828, 2001.
21. Rivera VM, Miranti CK, Misra RP, Ginty DD, Chen RH, Blenis J, Greenberg ME. A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity. Mol Cell Biol 13: 6260-6273, 1993.
22. Schlesinger J, Schueler M, Grunert M, Fischer JJ, Zhang Q, Krueger T, Lange M, Tonjes M, Dunkel I, Sperling SR. The cardiac transcription network modulated by Gata4, Mef2a, Nkx2.5, Srf, histone modifications, and microRNAs. PLoS Genet 7: e1001313, 2011.
23. Sheikh F, Raskin A, Chu PH, Lange S, Domenighetti AA, Zheng M, Liang X, Zhang T, Yajima T, Gu Y, Dalton ND, Mahata SK, Dorn GW, 2nd Brown JH, Peterson KL, Omens JH, McCulloch AD, Chen J. An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. J Clin Invest 118: 3870-3880, 2008.
24. Spinale FG, Janicki JS, Zile MR. Membrane-associated matrix proteolysis and heart failure. Circ Res 112: 195-208, 2013.
25. Tardiff JC. Thin filament mutations: developing an integrative approach to a complex disorder. Circ Res 108: 765-782, 2011.
26. Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Moore RL, Schwartz S, Robbins J, Leinwand LA. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest 101: 2800-2811, 1998.
27. Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, Robbins J, Leinwand LA. Cardiac troponin T mutations result in allelespecific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest 104: 469-481, 1999.
28. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, Nayor M, Konno T, Gorham JM, Wolf CM, Kim JB, Schmitt JP, Molkentin JD, Norris RA, Tager AM, Hoffman SR, Markwald RR, Seidman CE, Seidman JG. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest 120: 3520-3529, 2010.
29. Thierfelder L, MacRae C, Watkins H, Tomfohrde J, Williams M, McKenna W, Bohm K, Noeske G, Schlepper M, Bowcock A, Vosberg HP, Seidman JG, Seidman C. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci USA 90: 6270-6274, 1993.